AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

Essential breast cancer medicines

ESMO 2025: Highlights and analysis

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

Enhancing breast cancer care through AI and collaboration